Gold salts, D-penicillamine and allopurinol

  • Shiro Ueda
  • George A. Porter

Gold salts have been used in the treatment of patients with rheumatoid arthritis since 1927 [1]. After a controlled study, the Empire Rheumatism Council [2], confirmed the effectiveness of gold salts for the treatment of rheumatoid arthritis. Even today, chrysotherapy has remained one of the major therapeutic modalities in the second line treatment of progressive rheumatoid arthritis. Gold salts are also used in the treatment of pemphigus vulgaris [3] and bronchial asthma [4]. Before the introduction of an orally administered gold compound, auranofin (triethylphosphine gold tetra-acetyl glycopyranoside), to clinical use [5-7], parenterally administered gold salts, such as sodium aurothiomalate and gold thioglucose comprised chrysotherapy. The frequency and severity of the side effects for patients treated with parenteral gold versus those given oral gold preparations are significantly different [8-10]. With introduction of newer parental DMARDs, toxicity has been reduced using combination therapy [10a, 10b].


Rheumatoid Arthritis Rheumatoid Arthritis Patient Tumor Lysis Syndrome Gold Salt Sodium Aurothiomalate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lande K. Die gunstige Beeinflussung schleichender Dauerinfekte durch Solganal. Munchen Med Wochenshr 1927; 74: 1132-1134.Google Scholar
  2. 2.
    The Research Sub-Committee of the Empire Rheumatism Council. Gold therapy in rheumatoid arthritis. Final report of a multi-center controlled trial. Ann Rheum Dis 1961; 20: 315-333.Google Scholar
  3. 3.
    Penneys NS, Eaglestein WH, Frost P. Management of pemphigus with gold compounds. Arch Dermatol 1976; 112: 185-187.PubMedGoogle Scholar
  4. 4.
    Muranaka M, Miyamoto T, Shida T, Kabe J, Makino S, Okumura H, Takeda K, Suzuki S, Horiuchi Y. Gold salt in the treatment of bronchial asthma - a double blind study. Ann Allergu 1978; 40: 132-137.Google Scholar
  5. 5.
    Finkelstein AE, Walz DT, Batista V, Mizrazi M, Roisman F, Misher A. Auranofin - new oral gold compound for treatment of rheu-matoid arthritis. Ann Rheum Dis 1976; 35: 251-257.PubMedGoogle Scholar
  6. 6.
    Berglof FE, Berglof K, Walz DT. Auranofin: an oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. J Rheumatol 1978; 5: 68-74.PubMedGoogle Scholar
  7. 7.
    Weisman MH, Hannifin DH. Management of rheumatoid arthritis with oral gold. Arthritis Rheum 1979; 22: 922-925.PubMedGoogle Scholar
  8. 8.
    Davis P, Menard H, Thompson J, Harth M, Beaudet F. One-year comparative study of gold sodium thiomalate and auranofin in the treatment of rheumatoid arthritis. J Rheumatol 1985; 12: 60-67.PubMedGoogle Scholar
  9. 9.
    Ward JR, Williams HJ, Egger MJ, Reading JC, Boyce E, Altz-Smith M, Samuelson CO, Willkens RF, Solsky MA, Hayes SP, Blocka KL, Weinstein A, Meenan RF, Guttadauria M, Kaplan SB, Klippel J. Comparison of auranofin, gold sodium thiomalate and placebo in the treatment of rheumatoid arthritis: A controlled clinical trial. Arthritis Rheum 1983; 26: 1303-1315.Google Scholar
  10. 10.
    Heuer MA, Pietrusko RG, Morris RW, Scheffler BJ. An analysis of worldwide safety experience with auranofin. J Rheumatol 1985; 12: 695-699.PubMedGoogle Scholar
  11. 10a.
    O’Dell JR, Petersen K, Leff R, Palmer W, Schned E, Blakely K, Haire C, Fernandez A. Etanercept in combination with sulfasalaazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. J Rheumatol 2006;33:213-218.PubMedGoogle Scholar
  12. 10b.
    Rau R, Schleusser B, Herborn G, Karger T. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compare to MTX monotherapy. J Rheumatol 1998;25:1485-1492.PubMedGoogle Scholar
  13. 11.
    Hartfall SJ, Garland HG, Goldie W. Gold treatment of arthritis. A review of 900 cases. Lancet 1937; 9: 838-842.Google Scholar
  14. 12.
    Gibbons RB. Complication of chrysotherapy. A review of recent studies. Arch Intern Med 1979; 139: 343-346.PubMedGoogle Scholar
  15. 13.
    Penneys NS, Ackerman AB, Gottlieb NL. Gold dermatitis. Arch Dermatol 1979; 109: 372-376.Google Scholar
  16. 14.
    Benson WG, Moore N, Tugwell P, D, Souza M, Singal DP. HLA antigens and toxic reactions to sodium aurothiomalate in patients with rheumatoid arthritis. J Rheumatol 1984; 11: 358-361.Google Scholar
  17. 15.
    Adachi JD, Bensen WG, Singal DP, Powers PJ. Gold-induced thrombocytopenia: platelet associated IgG and HLA typing in three patients. J Rheumatol 1984; 11: 355-357.PubMedGoogle Scholar
  18. 16.
    Gottlieb NL, Gray RG. Diagnosis and management of adverse reaction from gold compounds. J Analytic Toxicol 1978; 2: 173.Google Scholar
  19. 17.
    Baldwin JL, Storb R, Thomas ED, Mannik M. Bone marrow transplantation in patients with gold-induced marrow aplasia. Arthritis Rheum 1977; 20: 1043-1048.PubMedGoogle Scholar
  20. 18.
    Gibson J, McGirr EE, York J, Kronenberg H. Aplastic anemia in association with gold therapy for rheumatoid arthritis. Aust NZ J Med 1983; 13: 130-135.Google Scholar
  21. 19.
    Winterbauer RH, Wilske KR, Wheelis RF. Diffuse pulmonary injury associated with gold treatment. N Engl J Med 1976; 294: 919-921.PubMedGoogle Scholar
  22. 20.
    Partanen J, van Assendelft AHW, Koskimies S, Forsberg S, Hakala M, Ilonen J. Patients with rheumatoid arthritis and fold-induced pneumonitis express two high-risk major histocompatibility complex patterns. Chest 1987; 92: 277-281.PubMedGoogle Scholar
  23. 21.
    Fam AG, Paton TW, Shamess CJ, Lewis AJ. Fulminant colitis complicating gold therapy. J Rheumatol 1980; 7: 479-485.PubMedGoogle Scholar
  24. 22.
    Silverberg DS, Kidd EG, Shnitka TK, Ulan RA. Gold nephropathy. A clinical and pathological study. Arthritis Rheum 1970; 13: 812-825.PubMedGoogle Scholar
  25. 23.
    Kean WF, Anastassiades TP. Long-term chrysotherapy. Incidence of toxicity and efficacy during sequential time periods. Arthritis Rheum 1979; 22: 495-501.PubMedGoogle Scholar
  26. 24.
    Katz WA, Blodgett RC Jr, Pietrusko RG. Proteinuria in gold treated rheumatoid arthritis. Ann Intern Med 1984; 101: 176-179.PubMedGoogle Scholar
  27. 25.
    Brock H, Han MT. Gold nephrosis. N Engl J Med 1966; 274: 210-211.Google Scholar
  28. 26.
    Furst DE, Levine S, Srinivasan R, Metzger L, Bangert R, Paulus E. A double-blind trial of high versus conventional dosages of gold salts for rheumatoid arthritis. Arthritis Rheum 1977; 20: 1473-1480.PubMedGoogle Scholar
  29. 27.
    Gran JT, Husby G, Thorsby E. HLA DR antigens and gold toxicity. Ann Rheum Dis 1983; 42: 63-66.PubMedGoogle Scholar
  30. 28.
    Bensen WG, Moore N, Tugwell P, D Souza M, Singal DP. HLA antigens and toxic reactions to sodium aurothiomalate in patients with rheumatoid arthritis. J Rheumatol 1984; 11: 358-361.PubMedGoogle Scholar
  31. 29.
    Barger BO, Acton RT, Koopman WJ, Alarcon GS. DR antigens and gold toxicity in white rheumatoid patients. Arthritis Rheum 1984; 27: 601-605.PubMedGoogle Scholar
  32. 30.
    Hakala M, van Assendelef AHW, Ilonen J, Jalava S, Tiilikainen A. Association of different HLA antigens with various toxic effects of gold salts in rheumatoid arthritis. Ann Rheum Dis 1986; 45: 177-182.PubMedGoogle Scholar
  33. 31.
    Vaamaonde CA, Hunt FR. The nephritic syndrome as a complication of gold therapy. Arthritis Rheum 1970; 13: 826-834.Google Scholar
  34. 32.
    Francis KL, Jenis EH, Jensen GE, Calcagno PL. God-associated nephropathy. Arch Pathol Lab Med 1984; 108: 234-238.PubMedGoogle Scholar
  35. 33.
    Hall CL, Fothergill NJ, Blackwell MM, Harrison PR, MacKenzie JC, Maclver AG. The natural course of gold nephropathy: long term study of 21 patients. Br Med J 1987; 295: 745-748.Google Scholar
  36. 34.
    Tornroth T, Skrifvars B. Gold nephropathy. Prototype of membranous glomerulonephritis. Am J Med 1974; 75: 573-590Google Scholar
  37. 34a.
    Hall CL. Gold nephropathy. Nephron 1988;50:265-272.PubMedGoogle Scholar
  38. 34b.
    Hall CL, The natural course of gold and penicillamine nephropathy. A longterm study of 54 patients. Adv. Exp Med Biol 1989;252:247-256/PubMedGoogle Scholar
  39. 34c.
    Klinkhoff AV, Teufel A. Reinstitution of gold after gold induced proteinuria. J Rheumatol 1997;24:1277-1279.PubMedGoogle Scholar
  40. 35.
    Lee JC, Dushinkin M, Eyring EJ, Engleman EP, Hopper JR. Renal lesions associated with gold therapy. Light and electron microscopic studies. Arthritis Rheum 1965; 8: 1-13.PubMedGoogle Scholar
  41. 36.
    Mattson JC. Glomerular diseases as a complication of gold therapy. Lab Invest 1974; 30: 383.Google Scholar
  42. 37.
    Katz A, Little AH. Gold nephropathy. An immunopathologic study. Arch Pathol 1973; 96: 133-136.PubMedGoogle Scholar
  43. 38.
    Watanabe I, Whitter FC, Moore J, Cuppage FE. Gold nephropathy. Ultrastructural fluorescent and microanalytic study of two human cases. Arch Path Lab Med 1976; 100: 632-635.PubMedGoogle Scholar
  44. 39.
    Davies DJ, Dowling J, Xipell JM. Gold nephropathy. Pathology 1977; 9: 281-288.PubMedGoogle Scholar
  45. 40.
    Skrifvars BV, Tornroth TS, Tallqvist GN. Gold-induced immune complex nephritis in seronegative rheumatoid arthritis. Ann Rheum Dis 1977; 36: 549-556.PubMedGoogle Scholar
  46. 41.
    Wolters J, Frederik P, van Rie H, Zeppenfeldt E. Minimal change nephropathy during gold treatment. A case with unusual his- topathological and immunopathological features. Netherland J Med 1987; 31: 234-240.Google Scholar
  47. 42.
    Skirfvars B, Tornroth T, Flalck HM. Granulomatous glomerulonephritis in a patient with rheumatoid arthritis treated with gold salts. Scand J Rheumatol 1979; 8: 234-240.Google Scholar
  48. 43.
    Cramer CR, Hagler HK, Silva FG, Eigenbrodt EH, Meltzer JI, Pirani CL. Chronic interstitial nephritis associated with gold nephropathy. Arch Path Lab Med 1983; 107: 258-263.PubMedGoogle Scholar
  49. 44.
    Tubbs RR, Valenzuela R, McGorman LJ, Pohl MA, Barenberg S. Gold nephropathy. New Eng J Med 1977; 296: 1413-1414.PubMedGoogle Scholar
  50. 45.
    Yarom R, Stein H, Peter PD, Slavin S, Hall TA. Nephrotoxic effect of parenteral and intraarticular gold. Ultrastructural and electron microprobe examination of clinical and experimental materials. Arthritis Rheum 1975; 99: 36-43.Google Scholar
  51. 46.
    Iesato K, Mori Y, Ueda S, Wakashin Y, Wakashin M, Matsui N, Inoue S, Okuda K. Renal tubular dysfunction as a complication of gold therapy in patients with rheumatoid arthritis. Clin Nephrol 1982; 17: 46-52.PubMedGoogle Scholar
  52. 47.
    Ueda S, Wakashin M, Wakashin Y, Yoshida H, Iesato K, Mori T, Mori Y, Akikusa B, Okuda K. Experimental gold nephropathy in guinea pigs: Detection of autoantibodies to renal tubular antigens. Kidney Int 1986; 29: 539-548.PubMedGoogle Scholar
  53. 48.
    Nagi AH, Alexander F, Barabas AZ. Gold nephropathy in rats. Light and electron microscopic studies. Exp Molec Path 1971; 15:354-362.PubMedGoogle Scholar
  54. 49.
    Eiseman JL, Ribas JL, Knight E, Alvares AP. Acute nephropathy induced by gold sodium thiomalate: Alterations in renal heme metabolism and morphology. Toxicol Appl Pharmacol 1987; 91: 193-203.PubMedGoogle Scholar
  55. 50.
    Bretza J, Wells I, Novey HS. Association of IgE antibodies to sodium aurothiomalate and adverse reactions to chrysotherapy for rheumatoid arthritis. Am J Med 1983; 74: 945-950.PubMedGoogle Scholar
  56. 51.
    Davis P, Ezeoke A, Munro J, Hobbs JR, Hughes GRV. Immunological studies on the mechanism of gold hypersensitivity reactions. Br Med J 1973; 3: 676-678.PubMedGoogle Scholar
  57. 52.
    Denman EJ, Denman AM. The lymphocyte transformation test and gold hypersensitivity. Ann Rheum Dis 1968; 27: 582-588.PubMedGoogle Scholar
  58. 53.
    Derot M, Kahn J, Mazalton A, Peyrafort J. Fatal anuric nephritis with associated chrysocyanosis following gold therapy. Bull Soc Med Hop Paris 1954; 70: 234-239.PubMedGoogle Scholar
  59. 54.
    Palosuo T, Provast TT, Milgrom F. Gold nephropathy. Serologic data suggesting an immune complex disease. Clin Exp Immunol 1976; 25: 311-318.PubMedGoogle Scholar
  60. 55.
    Skirfvars B. Hypothesis for the pathogenesis of sodium aurothiomalate induced immune complex nephritis. Scand J Rheumatol 1979; 8: 113-118.Google Scholar
  61. 56.
    Jessop JD, Vernon-Roberts B, Harris J. Effects of gold salts and prednisolone on inflammatory cells. I. Phagocytic activity of macrophages and polymorphs in inflammatory exudates studied by a ‘skin-window’ technique in rheumatoid and control patients. Ann Rheum Dis 1973; 32: 294-300.PubMedGoogle Scholar
  62. 57.
    Vernon-Roberts B, Jessop JD, Dore J. Effects of gold salts and prednisolone on inflammatory cells. II. Suppression of inflammation and phagocytosis in the rat. Ann Rheum Dis 1973; 32: 301-307.PubMedGoogle Scholar
  63. 58.
    Panush RS. Effects of certain antirheumatic drugs on normal human peripheral blood lymphocytes. Inhibition of mitogen- and antigen- stimulated incorporation of tritiated thymidine. Arthritis Rheum 1976; 19: 907-917.PubMedGoogle Scholar
  64. 59.
    Harth M, Stiller CR, Sinclair C, Evans J, McGirr D, Zuberi R. Effects of a gold salt on lymphocyte responses. Clin Exp Immunol 1977; 27: 357-364.PubMedGoogle Scholar
  65. 60.
    Measel W. Effects of gold on the immune response of mice. Infect Immunity 1975; 11: 350-354.Google Scholar
  66. 61.
    Ueda S, Wakashin M, Wakashin Y, Yoshida H, Azemoto R, Iesato K, Mori T, Mori Y, Ogawa M, Okuda K. Autoimmune interstitial nephritis in inbred mice. Analysis of mouse tubular basement membrane antigen and genetic control of immune response to it. Am J Pathol 1988; 132: 304-318.PubMedGoogle Scholar
  67. 62.
    Ueda S, Wakashin Y, Yoshida H, Mori T, Mori Y, Azemoto R, Ogawa M, Kato I, Wakashin M. Gold nephropathy - effect of gold on immune response to renal tubular basement membrane (TBM) antigen in mice. In: Nephrotoxicity. In vitro to in vivo, animals to man. Bach BH, Lock EA, editors. Plenum, New York 1989; p. 139-145.Google Scholar
  68. 63.
    Lorber A, Kunishima D, Simon T. Selective inhibition of T suppressor lymphocytes during chrysotherapy [Abstract]. Clin Pharmacol Ther 1983; 303: 300-302.Google Scholar
  69. 64.
    Newton O, Swinburn WR, Swinson DR. Proteinuria with gold nephropathy: When should gold be permanently stopped? Br J Rheumatol 1983; 22: 11-17.PubMedGoogle Scholar
  70. 65.
    Howard-Lock HE, Lock CJL, Mewa A, Kean WF. D-penicillamine; Chemistry and clinical use in rheumatic disease. Sem Arthritis Rheum 1986; 15: 261-281.Google Scholar
  71. 66.
    Manthorpe R, Bendixen G. Auranofin in rheumatoid arthritis: Use in patients with side-effect or lack of effect to gold sodium thiomalate or gold thioglucose and/or D-penicillamine. Scand J Rheumatol 1988; 17: 401-405.PubMedGoogle Scholar
  72. 67.
    Panayi GS, Wooley P, Batchelor JR. Genetic basis of R.A. HLA antigen, disease manifestations and toxic reactions to drugs. Br Med J 1978; 11: 1326-1328.Google Scholar
  73. 68.
    Wooly PH, Griffen J, Panayi GS, Batchelor JR, Welsh KI, Gibson TJ. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med 1980; 303: 300-302.CrossRefGoogle Scholar
  74. 69.
    Bardin T, Legrand L, Naveau B, Marcelli-Barge A, Debeyre N, Lathrop GM, Poirier JC, Schmid M, Ryckewaert A, Dryll A. HLA antigens and seronegative rheumatoid arthritis. Ann Rheum Dis 1985; 44: 50-53.PubMedGoogle Scholar
  75. 70.
    Dequeker J, Van Wanghe P, Verdickt W. A systematic survey of HLA-A, B, C, and D antigens and drug toxicity in rheumatoid arthritis. J Rheumatol 1984; 11: 282-286.PubMedGoogle Scholar
  76. 71.
    Ford PM. HLA antigens and drug toxicity in rheumatoid arthritis. J Rheumatol 1984; 11: 269-261.Google Scholar
  77. 72.
    Van Riel PL, Van de Putte LB, Gribnau FW, de Waal RM. Serum IgA and gold induced toxic effects in patients with rheumatoid arthritis. Arch Intern Med 1984; 144: 1401-1403.PubMedGoogle Scholar
  78. 73.
    Ostuni PA, Simioni M, Marson P, Travaglia P, Volante D, Gambari PF. Serum IgA and gold toxicity in rheumatoid arthritis: lack of predicting value. Clin Exp Rheumatol 1986; 4: 359-362.PubMedGoogle Scholar
  79. 74.
    Ayesh R, Mitchell SC, Waring RH, Withrington RH, Seifert MH, Smith RL. Sodium aurothiomalate toxicity and sulphoxidation capacity in rheumatoid arthritis patients. Br J Rheumatol 1987; 26: 197-201.PubMedGoogle Scholar
  80. 74a.
    Shah P, Griffith SM, Shadforth MF, Fisher J, Dawes PT, Poulton KV, Thomson W, Ollier WE, Mattey DL. Can gold ltherapy be used more safely in rheumatoid arthritis? Adverse drug reactions are more likely in patients with nodular disease, independent of HLA-DR3 status. J Rheumatol 2004;31:1903-1905.PubMedGoogle Scholar
  81. 74b.
    Pissuwan D, Vlaenzuela SM, Cortie MB. Therapeutic possibilities of plasmonicall heated gold nanoparticles. Trends in Biotech. 2006;24:62-67Google Scholar
  82. 74c.
    Zharov VP, Galitovskaya EN, Johnson C, Kelly T. Synergistic enhancement of selective nanophotothermolysis with gold nanoclusters: Potential for cancer therapy. Lasers in Surg Med. 2005;37:219-226.Google Scholar
  83. 75.
    Blodgett RC Jr, Heuer MA, Pietrusko RG. Auranofin: a unique oral chrysotherapeutic agent. Semin Arthritis Rheum 1984; 13:255-273.PubMedGoogle Scholar
  84. 76.
    Bandilla K, Gross D, Gross W, Herrlinger J-D, Kriegel W, Muller W, Siegmeth W, Tausch G, Thumb N, Wagenhauser J. Oral gold therapy with auranofin (SK&F39162). J Rheumatol 1982; 9 (Suppl 8): 154-159.Google Scholar
  85. 77.
    Katz W, Alexander S, Bland J, Blechman W, Bluhm GB, Bonebrake Ra, Falbo A, Greenwald RA, Hartman S, Hobbs T, Indenbaum S, Lergier JE, Lanier BG, Lightfoot RW, Phelps P, Sheon RP, Torretti D, Wenger ME, Wilske K. The efficacy and safety of auranofin compared to placebo in rheumatoid arthritis. J Rheumatol 1982; 9 (Suppl 8): 173-178.Google Scholar
  86. 78.
    Wenger ME, Alexander S, Bland JH, Blechman WJ. Auranofin versus placebo in the treatment of rheumatoid arthritis. Am J Med 1983; 75: 123-127.PubMedGoogle Scholar
  87. 79.
    Menard HA, Beaudet F, Davis O, Harth M, Percy JS, Russell AS, Thompson M. Gold therapy in rheumatoid arthritis. Interim report of the Canadian multicentre prospective trial comparing sodium aurothiomalate and auranofin. J Rheumatol 1982; 9: 179-183.Google Scholar
  88. 80.
    Felix-Davies DD, Stewart AM, Wilkinson BR, Bateman JR, Delamere JP. A 12-month comparative trial of auranofin and D-penicil-lamine in rheumatoid arthritis. Am J Med 1983; 75(6A): 138-141.PubMedGoogle Scholar
  89. 81.
    Manthrope R, Horbov S, Sylvest J, Vinterberg H. Auranofin versus penicillamine in rheumatoid arthritis. One-year results from a prospective clinical investigation. Scand J Rheumatol 1986; 15: 13-22.Google Scholar
  90. 82.
    Hochberg MC. Auranofin or D-penicillamine in the treatment of rheumatoid arthritis. Ann Intern Med 1986; 105: 528-535.PubMedGoogle Scholar
  91. 83.
    Revach M, Freed RL, Ehrlich GE. Reversible proteinuria as a complication of oral gold therapy [Letter]. Arthritis Rheum 1979; 22: 1417-1418.PubMedGoogle Scholar
  92. 84.
    Plaza JJ, Herrero G, Barat A, Loutaif JJ, Hernando L, Vallado P, Oliva H. Membranous glomerulonephritis as a complication of oral gold therapy [Letter]. Ann Intern Med 1982; 97: 563-564.PubMedGoogle Scholar
  93. 85.
    Gottlieb NL. Comparative pharmacokinetics of parenteral and oral gold compounds. J Rheumatol 1982; 9 (Suppl 8): 99-109.Google Scholar
  94. 86.
    Blocka K. Auranofin versus injectable gold: Comparison of pharmacokinetic properties. Am J Med 1983; 75(6A): 114-122.PubMedGoogle Scholar
  95. 87.
    Abraham EP, Chain E, Baker W, Robinson R. Penicillamine, a characteristic degradiation product of penicillin. Nature 1943; 151: 107.Google Scholar
  96. 88.
    Walshe JM: Penicillamine. A new oral therapy for Wilson’s disease. Am J Med 1956; 2: 487-495.Google Scholar
  97. 89.
    Drawhall JC, Scowen EF, Watts RWE. Effects of penicillamine on cystinuria. Br Med J 1963; 1: 588-590.Google Scholar
  98. 90.
    Jaffe IA. Intra-articular dissociation of the rheumatoid factor. J Lab Clin Med 1962; 60: 409-421.PubMedGoogle Scholar
  99. 91.
    Jaffe IA. The effect of penicillamine in the laboratory parameters in rheumatoid arthritis. Arthritis Rheum 1965; 8: 1064-1078.PubMedGoogle Scholar
  100. 92.
    Multicenter trial group. Controlled trial of D-penicillamine in severe rheumatoid arthritis. Lancet 1973; 1: 275-280.Google Scholar
  101. 93.
    Steen VD, Medsger TA, Rodnan GP. D-penicillamine therapy in progressive systemic sclerosis (scleroderma). A retrospective analysis. Ann Intern Med 1982; 97: 652-659.PubMedGoogle Scholar
  102. 94.
    Jain S, Scherer PJ, Samourian S. A controlled trial of D-penicillamine therapy in primary biliary cirrhosis. Lancet 1977; 1: 831-834.PubMedGoogle Scholar
  103. 95.
    Goldberg Am Smith JA, Lochhead AC. Treatment of lead poisoning with oral penicillamine. Br Med J 1963; 1: 1270-1275.Google Scholar
  104. 96.
    Freeman HC, Huq F, Stevens GN: Metal binding by D-penicillamine: Crystal structure of D-penicillamine cadmium (II) hydrate. J Chem Soc Chem Commun 1976; 90-91.Google Scholar
  105. 97.
    Tamir M, Boustein B, Behar M, Chwat M. Mercury poisoning from an unsuspected source. Br J Ind Med 1968; 21: 299-303.Google Scholar
  106. 98.
    Deutsch MF, Morton JI. Dissociation of human serum macroglobulins. Science 1957; 125: 600-601.PubMedGoogle Scholar
  107. 99.
    Kean WF, Dwosh JL, Anastassiades TP, Ford PM, Kelly HG. The toxicity pattern of D-penicillamine therapy. A guide to the use in RA. Arthritis Rheum 1980; 23: 158-165.PubMedGoogle Scholar
  108. 100.
    Stein HB, Patterson AC, Offer RC, Atkins CJ, Teufel A, Robinson HS. Adverse effects of D-penicillamine in rheumatoid arthritis. Ann Intern Med 1980; 92: 24-29.PubMedGoogle Scholar
  109. 101.
    Kean WF, Lock CJL, Howard-Lock HE, Buchanan WW. Prior gold therapy does not influence the adverse effects of D-penicillamine in rheumatoid arthritis. Arthritis Rheum 1982; 25: 917-922.PubMedGoogle Scholar
  110. 102.
    Wollheim FA, Lindstrom CG. Liver abnormalities in penicillamine treated patients with rheumatoid arthritis. Scand J Rheumatol 1979; 28 (Suppl):100-107.Google Scholar
  111. 103.
    Barzilai D, Dickstein G, Enat R, Bassan H, Lichtig C, Gellei B. Cholestatic jaundice caused by D-penicillamine. Ann Rheum Dis 1978; 37: 98-100.PubMedGoogle Scholar
  112. 104.
    Multz CV. Cholestatic hepatitis caused by penicillamine. JAMA 1981; 246: 674-675.PubMedGoogle Scholar
  113. 105.
    Hickling P, Fuller J. Penicillamine causing acute colitis. Br Med J 1979; 2: 367.PubMedGoogle Scholar
  114. 106.
    Crawhall JC. Proteinuria in D-penicillamine-treated rheumatoid arthritis. J Rheumatol 1981; 8: 161-163.Google Scholar
  115. 107.
    Davison AM, Day AT, Golding JR, Thomson D. Effect of penicillamine on the kidney. Proc R Soc Med 1977; 70: 109-113.PubMedGoogle Scholar
  116. 108.
    Barraclough D, Cunningham TJ, Muirden KD. Microscopic haematuria in patients with rheumatoid arthritis on D-penicillamine. Aust NZ J Med 1981; 11: 706-708.Google Scholar
  117. 109.
    Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheu-matoid arthritis. J Rheumatol 1991;18: 188-194.PubMedGoogle Scholar
  118. 110.
    Weiss AS, Markenson JA, Weiss MS, Kammerer WH. Toxicity of D-penicillamine in rheumatoid arthritis. A report of 63 patients including two with aplastic anemia and one with the nephritic syndrome. Am J Med 1978; 64: 114-120.PubMedGoogle Scholar
  119. 111.
    Chalmers A, Thompson D, Stein HE, Reid G, Patterson HC. Systemic Lupus Erythematosus during penicillamine therapy for rheumatoid arthritis. Ann Intern Med 1982; 97: 659-663.PubMedGoogle Scholar
  120. 112.
    Walshe JM. Penicillamine and the SLE syndrome. J Rheumatol 1981; 8 (Suppl 7): 155-160.Google Scholar
  121. 113.
    Sternlieb I, Bennet B, Scheinberg IH. D-penicillamine induced Goodpasture’s syndrome in Wilson’s disease. Ann Intern Med 1975; 82: 673.PubMedGoogle Scholar
  122. 114.
    Gibson T, Barry HC, Ogg C. Goodpastures’ syndrome and D-penicillamine. Ann Intern Med 1976; 84: 100.PubMedGoogle Scholar
  123. 115.
    Gavaghan TE, McNaught PJ, Ralston M, Hayes JM. Penicillamine-induced ‘Goodpasture’s syndrome’; successful treatment of a fulminant case. Aust NZ J Med 1981; 11: 261-265.Google Scholar
  124. 116.
    Jaffe IA. The treatment of rheumatoid arthritis and necrotizing vasculitis with penicillamine. Arthritis Rheum 1970; 13: 436-443.PubMedGoogle Scholar
  125. 117.
    Banfi G, Imbasciati E, Guerra L, Mihatsch MJ, Ponticelli C. Extracapillary glomerulonephritis with necrotizing vasculitis in D-peni-cillamine treated patients with rheumatoid arthritis. Nephron 1983; 33: 56-60.PubMedGoogle Scholar
  126. 118.
    Torres CF, Griggs RC, Baum J, Penn AS. Penicillamine induced myasthenia gravis in progressive sclerosis. Arthritis Rheum 1980; 23: 505-508.PubMedGoogle Scholar
  127. 119.
    Dawkins RL, Garlepp MJ, McDonald BL, Williamson J. Myasthenia gravis and D-penicillamine. J Rheumatol 1981; 8 (Suppl 7): 169-174.Google Scholar
  128. 120.
    Vincent A, Newsom-Davis J. Acetylcholine receptor antibody characteristic in myasthenia gravis. Patients with penicillamine-induced myasthenia or idiopathic myasthenia of recent onset. Clin Exp Immunol 1982; 49: 266-272.PubMedGoogle Scholar
  129. 121.
    Bever CT, Chang HW, Penn AS, Jaffe IA, Bock E. Penicillamine induced myasthenia gravis. Effects of penicillamine on acetylcholine receptor. Neurology 1982; 32: 1077-1082.PubMedGoogle Scholar
  130. 122.
    Bocanegra T, Espinoza LR, Vassey FB, Germain BF. Myasthenia gravis in penicillamine treatment of RA. JAMA 1980; 244: 1822-1823.PubMedGoogle Scholar
  131. 123.
    Cucher BG, Goldman AL. D-penicillamine induced polymyositis in RA. Ann Intern Med 1976; 85: 615-618.PubMedGoogle Scholar
  132. 124.
    Schreider PL, Peters HA, Dahl DS. Polymyositis and penicillamine. Arch Neurol 1972; 27: 456-457.Google Scholar
  133. 125.
    Wojnarowska F. Dermatomyositis induced by penicillamine. J R Soc Med 1980; 73: 884.PubMedGoogle Scholar
  134. 126.
    Halverson PB, Kozin F, Bernhard GC, Goldman AL. Toxicity of penicillamine. A serious limitation to therapy in rheumatoid arthritis. JAMA 1978; 240: 1870-1871.PubMedGoogle Scholar
  135. 127.
    Steen VD, Blair S, Medsger TA. The toxicity of D-penicillamine in systemic sclerosis. Ann Intern Med 1986; 104: 699-705.PubMedGoogle Scholar
  136. 128.
    Moens HJB, Ament BJW, Feltkamp BW, Korst JK. Longterm followup of treatment with D-penicillamine to rheumatoid arthritis: effectivity and toxicity in relation to HLA antigens. J Rheumatol 1987; 14: 1115-1119.PubMedGoogle Scholar
  137. 129.
    Shiokawa Y, Horiuchi Y, Honma M, Kageyama T, Okada T, Azuma T. Clinical evaluation of D-penicillamine by multicentric double blind comparative study in chronic rheumatoid arthritis. Arthritis Rheum 1977; 20: 1464-1472.PubMedGoogle Scholar
  138. 130.
    Stockman A, Zilko PJ, Major GAC, Tait BD, Property DN, Mathews JD, Hannah MC, McCluskey J, Muirden KD. Genetic markers in rheumatoid arthritis-Relationship of toxicity from D-penicillamine. J Rheumatol 1986; 13: 269-273.PubMedGoogle Scholar
  139. 131.
    Hill HFH, Hill AGS, Day AT, Brown RM, Golding JR, Lyle WH. Maintenance dose of penicillamine in rheumatoid arthritis: A com-parison between standard and a response-related flexible regimen. Ann Rheum Dis 1979; 38: 429-433.PubMedGoogle Scholar
  140. 132.
    Williams HJ, Ward JR, Reading JC, Egger MJ, Grandone JT, Samuelson CO, Furst DE, Sullivan JM, Watson MA, Guttadauria M, Cathcart ES, Kaplan SB, Halla JT, Weinstein A, Plotz PH. Low dose D-penicillamine treatment of R.A. A controlled double blind clinical trial. Arthritis Rheum 1983; 26: 581-592.PubMedGoogle Scholar
  141. 133.
    Hill H, Hill A, Davison M. Resumption of treatment with penicillamine after proteinuria. Ann Rheum Dis 1979; 38: 229-231.PubMedGoogle Scholar
  142. 134.
    Billingsley LM, Stevens MB. The relationship between D-penicillamine-induced proteinuria and prior gold nephropathy. Johns Hopkins Med J 1981; 148: 64-67.PubMedGoogle Scholar
  143. 135.
    Halla JT, Cassidy J, Hardin JG. Sequential gold and penicillamine therapy in rheumatoid arthritis. Am J Med 1982; 72: 423-426.PubMedGoogle Scholar
  144. 136.
    Ross JH, McGinty F, Brewer DG. Penicillamine nephropathy. Nephron 1980; 26: 184-186.PubMedGoogle Scholar
  145. 137.
    Dische FE, Swinson DR, Hamilton EBD, Parsons V. Immunopathology of penicillamine-induced glomerular disease. J Rheumatol 1976; 3: 145-154.PubMedGoogle Scholar
  146. 138.
    Halla JT, Cassidy J, Hardin JG. Sequential gold and penicillamine therapy in rheumatoid arthritis. Am J Med 1982; 72: 423-426.PubMedGoogle Scholar
  147. 139.
    Bacon PA, Tribe CR, MacKenzie JC, Jones JV, Cumming RH, Amer B. Penicillamine nephropathy in rheumatoid arthritis. Q J Med 1976; 45: 661-684.PubMedGoogle Scholar
  148. 140.
    Jaffe IA, Treser G, Suzuki Y, Ehrenreich T. Nephropathy induced by D-penicillamine. Ann Intern Med 1968; 69: 549-556.PubMedGoogle Scholar
  149. 141.
    Swinson DR, Hamilton EBD, Dische FE. Penicillamine nephropathy [letter]. Ann Rheum Dis 1975; 34: 544.PubMedGoogle Scholar
  150. 142.
    Neild GH, Gartner HV, Bohle A. Penicillamine induced membranous nephritis. Scand J Rheumatol 1979; 28: 79-90.Google Scholar
  151. 143.
    Sellars L, Siamopoulos K, Wilkinson R, Leohapand T, Morley AR. Renal biopsy appearances in rheumatoid disease. Clin Nephrol 1983; 20: 114-120.PubMedGoogle Scholar
  152. 144.
    Herve JP, Leguy P, Cledes J, Leroy JP. Nephrotic syndrome with minimal glomerular lesions during treatment with D-penicillamine. Nouv Press Med 1980; 9: 2847.Google Scholar
  153. 145.
    Kitazawa K, Ohseto Y, Kawazumi H, Saito K, Shibata T, Uchida J, Yonekura M, Schiwachi S, Ito S, Sugisaki T. D-penicillamine induced lipoid nephrosis in a patient with scleroderma. Ryumachi 1982; 22: 397-403.PubMedGoogle Scholar
  154. 146.
    Hayslett JP, Bensch KG, Kashgarian MZ, Rosenberg LE. Focal glomerulitis due to penicillamine. Lab Invest 1968; 19; 376-381.PubMedGoogle Scholar
  155. 147.
    Rehan A, Johnson K. IgM Nephropathy associated with penicillamine. Am J Nephrol 1986; 6: 71-74.PubMedGoogle Scholar
  156. 148.
    Liao K, Huang CC, Ho HH, Wu CH, Hsueh S. IgM nephropathy after D-penicillamine therapy: Report of a case. J Formosan Med Assoc 1987; 86: 906-909.Google Scholar
  157. 149.
    Hall CL. Jawad S, Harrison PR, MacKenzie JC, Bacon PA, Klouda PT, Maclver AG. Natural course of penicillamine nephropathy: A long-term study of 33 patients. Br Med J 1988; 296: 1083-1086.Google Scholar
  158. 150.
    Jaffe IA. D-penicillamine. Bull Rheum Dis 1977-8; 28: 948-952.Google Scholar
  159. 151.
    Jaffe IA. Penicillamine in rheumatoid disease with particular reference to the rheumatic factor. Postgrad Med J 1968 (suppl): 34-40.Google Scholar
  160. 152.
    Swainson CP, Thompson D, Short AIK, Winney RJ. Plasma exchange in the successful treatment of drug-induced renal disease. Nephron 1982; 30: 244-249.PubMedGoogle Scholar
  161. 153.
    Peces R, Rivera JR, Arboleya LR, Lopez-Larrea C, Alvarez J. Goodpasture’s syndrome in a patient receiving penicillamine and carbimazole. Nephron 1985; 45: 316-320.Google Scholar
  162. 154.
    Matloff DS, Kaplan MM. D-penicillamine-induced Goodpasture’s-like syndrome in primary biliary cirrhosis: successful treatment with plasmapheresis and immunosuppressives. Gastroenterology 1980; 78: 1046-1049.PubMedGoogle Scholar
  163. 155.
    Devogelaer J-P, Pirson Y, Vandenbroucke J-M, Cosyns J-P, Brichard S, Deuxchaisnes CN. D-penicillamine induced crescentic glomerulonephritis: Report and review of the literature. J Rheumatol 1987; 14: 1036-1041.PubMedGoogle Scholar
  164. 155a.
    Derk CT & Jimenez SA. Goodpasture-like syndrome induced by d-penicillamine in a patient with systemic sclerosis: Report and review of the literature. J. Rheumatol 2003;30:1616-1620.PubMedGoogle Scholar
  165. 155b.
    Bienaime G, Clerbaux G, Plaisier E, Mougenot B. Ronco P, Rougier JP. D-penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease. Am J Kid Dis 2007;50:821-825.PubMedGoogle Scholar
  166. 156.
    Falck HM, Tornooth T, Kock B, Wegelius O. Fatal renal vasculitis with minimal change glomerulonephritis complicating treatment with penicillamine. Acta Med Scand 1979; 205: 133-138.PubMedGoogle Scholar
  167. 157.
    Ntoso KA, Tomaszewski JE, Jimenez SA, Neilson DG. Penicillamine-induced rapidly progressive glomerulonephritis in patients with progressive systemic sclerosis: Successful treatment of two patients and review of the literature. Am J Kidney Dis 1986; 8: 159-163.PubMedGoogle Scholar
  168. 158.
    Camus J-P, Homberg JC, Crouzet J, Mery C, Delrieu F, Massias P, Abuaf N. Autoantibody formation in D-penicillamine treated rheumatoid arthritis. J Rheumatol 1981; 7 (suppl): 80-83.Google Scholar
  169. 159.
    Mohammed I, Barraclough D, Holborrow EJ, Ansell BM. Effect of D-penicillamine therapy on circulating immune complexes in rheumatoid arthritis. Ann Rheum Dis 1976; 35: 458-462.Google Scholar
  170. 160.
    Aarden LA. Pathogencity of immune complexes. In: Non-articular forms of rheumatoid arthritis. Feltkamp TEW, editor. Stafleu’s Scientific Publishing Co, Leyden 1977; 15.Google Scholar
  171. 161.
    Kirby JD, Dieppe PA, Huskisson EC, Smith B. D-penicillamine and immune complex deposition. Ann Rheum Dis 1979; 38: 344-346.PubMedGoogle Scholar
  172. 162.
    Nagata N, Hurtenbach U, Gleichmann E. Specific sensitization of Lyt-1+2-stereoisomer. J Immunol 1986; 136: 136-142.PubMedGoogle Scholar
  173. 162a.
    Doyle MK and Cuellar ML. Drug-induced vasculitis. Expert Opin Drug Saf. 2003;2:401-409.PubMedGoogle Scholar
  174. 163.
    Emery P, Panayi GS, Huston G, Welsh KI, Mitchell SC, Shah RR, Idle JR, Smith RL, Waring RH. E-penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J Rheumatol 1984; 11: 626-632.PubMedGoogle Scholar
  175. 164.
    Speerstra F, Reekers P, van de Putte LBA, Vandenbroucke JP, Rasker JJ, de Rooij DJRAM. HLA-DR antigens and proteinuria induced by aurothioglucose and D-penicillamine in patients with rheumatoid arthritis. J Rheumatol 1983; 10: 948-953.PubMedGoogle Scholar
  176. 165.
    Moutsopoulos HM, Skopouli FN, Sarras AK, Tsampoulas C, Mavridis AK, Constantopoulos SH, Maddison PJ. Anti-Ro(SSA) positive rheumatoid arthritis: a clinicoserological group of patients with high incidence of D-penicillamine side effects. Ann Rheum Dis 1985; 44: 215-219.PubMedGoogle Scholar
  177. 166.
    Moutsopoulos HM, Giotaki H, Maddison PJ, Mavridis AK, Drosos AA, Skopouli FN. Antibodies to cellular antigens in Greek patients with autoimmune diseases: anti-Ro(SSA) antibody a possible marker of D-penicillamine intolerance. Ann Rheum Dis 1984; 43: 285-287.PubMedGoogle Scholar
  178. 167.
    Dodd MJ, Griffiths ID, Thomson M. Adverse reaction to D-penicillamine after gold toxicity. Br Med J 1980; 26: 1498-1500.Google Scholar
  179. 168.
    Webley M, Coomes EN. Is penicillamine therapy in RA. influenced by previous gold ? Br Med J 1978; 2: 91.PubMedGoogle Scholar
  180. 169.
    Klouda PT, Manos J, Acheson EJ, Dyer PA, Goldby FS, Harris R, Lawler W, Mallick NP, Williams G. Strong association between idiopathic membranous nephropathy and HLA-DRW3. Lancet 1979; 2: 770-771.PubMedGoogle Scholar
  181. 170.
    Swiss Federal Commission for the rheumatic diseases, Subcommission for Research. HLA-DR antigens in rheumatoid arthritis -A Swiss collaborative study; final report. Rheumatol Int 1986; 6: 89-92.Google Scholar
  182. 170a.
    Schiff MH and Whelton A. Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2000; 30:196-208.PubMedGoogle Scholar
  183. 171.
    Rundles RW, Wyngaarden JB, Hitchings GH, Elison B, Silberman HR. Effects of a xanthine oxidase inhibitor on thiopurine me-tabolism, hyperuricemia, and gout. Trans Assoc Am Physicians 1963; 76: 126-140.Google Scholar
  184. 172.
    Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med 1966; 64: 229-258.PubMedGoogle Scholar
  185. 173.
    Auerbach R, Orentrich N. Alopecia and ichthyosis secondary to allopurinol. Arch Dermatol 1968; 98: 104.PubMedGoogle Scholar
  186. 174.
    Boston Collaborative Drug Surveillance Program. Allopurinol and cytotoxic drugs. JAMA 1974; 227: 1036-1040.Google Scholar
  187. 175.
    Pinnas G. Possible association between macular lesions and allopurinol. Arch Ophthalmol 1968; 79: 786-787.PubMedGoogle Scholar
  188. 176.
    Korting HC, Lesch R. Acute cholangitis after allopurinol treatment. Lancet 1978; 1: 275-276.PubMedGoogle Scholar
  189. 117.
    Boyer TD, Sun N, Reynolds TB. Allopurinol-hypersensitivity. Vasculitis and liver damage. West J Med 1977; 126: 143-147.PubMedGoogle Scholar
  190. 178.
    Raper R, Barnes P, Ibels L, Lunzer M, Lauer C. Fulminant hepatic failure due to allopurinol. Aust NZ J Med 1984; 14: 63-65.Google Scholar
  191. 179.
    Bailey RR, Neale TJ, Lynn KL. Allopurinol-associated arteritis. Lancet 1976; 2: 907.PubMedGoogle Scholar
  192. 180.
    Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine stones, a rare complication of allopurinol therapy. N Eng J Med 1969; 280: 426-427.CrossRefGoogle Scholar
  193. 180a.
    LaRosa C, McMullen L, Bakdash S, Ellis D, Krishnamurti L, Wu HY, Mortiz ML. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol 2007;22:132-135PubMedGoogle Scholar
  194. 180b.
    Rebentisch G, Stolz s, Muche J. Xanthinuria with xantine lithiasis in a patient with Lesch-Nyhan syndrome under allopurinol therapy. Aktuelle Urol. 2004;215-221.Google Scholar
  195. 181.
    Jarzobski J, Ferry J, Womboldt D, Fitch DM, Egan JD: Vasculitis with allopurinol therapy. Am Heart J 1970; 79: 116-121.PubMedGoogle Scholar
  196. 182.
    Kantor GC. Toxic epidermal necrolysis, azotemia, and death after allopurinol therapy. JAMA 1970; 212: 478-479.PubMedGoogle Scholar
  197. 183.
    Mills RM. Severe hypersensitivity reactions associated with allopurinol. JAMA 1971; 216: 799-802.PubMedGoogle Scholar
  198. 184.
    Young JC, Boswell RB, Niles AS: Severe allopurinol hypersensitivity. Arch Intern Med 1974; 134: 553-558.PubMedGoogle Scholar
  199. 185.
    Gelbart DC, Weinstein AB, Fajardo CF. Allopurinol-induced interstitial nephritis. Ann Intern Med 1977; 86: 196-198.PubMedGoogle Scholar
  200. 186.
    Lupton GP, Odom RB. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol 1979; 1(4): 365-374.PubMedGoogle Scholar
  201. 187.
    Grussendorf M, Andrassy K, Waldherr R, Ritz E. Systemic hypersensitivity to allopurinol with acute interstitial nephritis. Am J Nephrol 1981; 1: 195-109.Google Scholar
  202. 188.
    Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 82-87.PubMedGoogle Scholar
  203. 188a.
    Tausche AK, Aringer M, Schroeder HE, Bornstein SR, Wunderlich C, Wozel G. The janus faces of allopurinol - Allopurinol Hyper-sensitivity Syndrome. Am J Med. 2008;121:e3-e4.PubMedGoogle Scholar
  204. 188b.
    Petersel D, Schlesinger N. Treatment of acute gout in hospitalized patients. J. Rheumatol 2007;34:1566-1568.PubMedGoogle Scholar
  205. 188c.
    Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein AC. Gunter MJ, Lafata JE, Harrold L, Nelson WW, Platt R. Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients. Ann Pharmacother 2006;40:386-391.PubMedGoogle Scholar
  206. 189.
    McMenamie RA, Davies LM, Crasswell OW. Drug induced interstitial nephritis, hepatitis and exfoliative dermatitis. Aust NZ J Med 1976; 6: 583-587.Google Scholar
  207. 190.
    McKendrick MW, Geddes AM. Allopurinol hypersensitivity. Br J Med 1979; i: 988.Google Scholar
  208. 191.
    Boyer TD, Sun N, Reynolds TB. Allopurinol-hypersensitivity. Vasculitis and liver damage. West J Med 1977; 126: 143-147.PubMedGoogle Scholar
  209. 191a.
    Morel D, Cuez S, Merville P, Deminiere C, Tamisier JM, Potaux L. Recurrent renal failure associated with hypersensitivity to al-lopurinol. Nephrol Dial Transplant 1999;14:780-781.PubMedGoogle Scholar
  210. 192.
    Emmerson BT, Hazelton RA, Frazer IH. Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol. Arthritis Rheum 1988; 31: 436-440.PubMedGoogle Scholar
  211. 193.
    Elion GB, Kovensky A, Hitchings GH. Metabolic studies of allopurinol, an inhibitory of xanthine oxidase. Biochem Pharmacol 1965; 15: 863-880.Google Scholar
  212. 194.
    Elion GB, Yu TF, Gutman AB, Hitchings GH. Renal clearance of oxypurinol, the chief metabolite of allopurinol. Am J Med 1968; 45: 69-77.PubMedGoogle Scholar
  213. 195.
    Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 47-56.PubMedGoogle Scholar
  214. 196.
    Simmonds HA, Cameron JS, Morris GS, Davies PM. Allopurinol in renal failure and the tumor lysis syndrome. Clin Chim Acta 1986; 31: 189-195.Google Scholar
  215. 197.
    Puig JP, Casas EA, Ramos TH, Michan AA, Mateos FA. Plasma oxypurinol concentration in a patient with allopurinol hypersensitiv-ity. J Rheumatol 1989; 16: 842-844.PubMedGoogle Scholar
  216. 198.
    Suzuki Y, Inagi R, Aono T, Yamanishi K, Shihara T. Human herpesvirus 6 infrction a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol 1998; 134: 1108-1112.PubMedGoogle Scholar
  217. 198a.
    Tiu RV, Mountantonakis SE, Dunbar AJ, Schreiber MJ Jr. Tumor lysis syndrome. Semin Thromb Hemost. 2007;33:397-407.PubMedGoogle Scholar
  218. 198b.
    Becker MA, Schumacher R Jr., Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Eng J Med 2005;353:2450-2461.Google Scholar
  219. 198c.
    Gelber AC. Febuxostat versus allopurinol for gout. N Engl J Med 2006;354:1532-1533.PubMedGoogle Scholar
  220. 198d.
    Stamp L, Searle M, O’Donnell J, Chapman P. Gout in solid organ transplantation; A challenging clinical problem. Drugs 2005;65:2593-2611.PubMedGoogle Scholar
  221. 198e.
    Sood AR, Burry LD, Cheng DKF. Clarifying the role of rasburicase in tumor lysis syndrome. Pharmacother 2007;27:11-=121.Google Scholar
  222. 198f.
    Bessmertny O, Robitaille LM, Cairo MS. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome. Cur-rent Pharmaceutical Design. 2005;11:4177-4185.Google Scholar
  223. 198g.
    Ronco C, Inguaggiato P, Bordoni V, DeCal M, Bonello M, Andrikos E, Assuman Y, Rattanarat R, Bellomo R. Rasburicase therapy in acute hyperuricemia and renal dysfunction. Contrib Nephrol 2005;147:115-123.PubMedGoogle Scholar
  224. 198h.
    Suh WM, Wainberg ZA, deVos S, Cohen AH, Kurtz I, Nguyen MK. Acute lymphoblastic leukemia presenting as acute renal failure. Naature Clin Pract. Nephrology 2007;3:106-110.PubMedGoogle Scholar
  225. 198i.
    DeAngelis S, Noce A, DiRenzo L, Cianci R, Naticchia A, Giarrizzo GR, Giordano F, Tozzo C, Splendiani G, DeLorenzo A. Is rasburicase an effective alternative to allopurinol for the management of hyperuricemia in renal failure patients/ A double -blind randomized study. Euro Rev Med Pharmacol Sci. 2007;11:179-184.Google Scholar
  226. 199.
    Kelley WN. Gout and related disorders of purine metabolism. In: Textbook of Rheumatology (1st edition). Kelly WN, Harris Jr ED, Sledge CB, editors. WB Saunders, Philadelphia 1981; p. 1397-1437.Google Scholar
  227. 200.
    Fam AG. Gout in the elderly. Drug & Aging. 1999;13:229-243.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Shiro Ueda
    • 1
  • George A. Porter
    1. 1.Department of Drug Information and Communication, Graduate School of PharmaceuticalChiba UniversityChiba CityJapan

    Personalised recommendations